2025 ASCO前瞻｜消化系统肿瘤Oral研究方向新趋势，抢先看

2025年美国临床肿瘤学会（ASCO）年会即将于5月30日至6月3日在美国芝加哥正式召开。本次ASCO年会消化系统肿瘤领域共有18项重磅口头报告（Oral）报告入选，涵盖结直肠癌、胃癌、胰腺癌、肝胆癌等高发癌种，聚焦于精准治疗、免疫联合、ctDNA指导策略、新型靶点开发与术前/围手术期治疗优化等热点：

• 研究阶段以III期注册研究为主，验证新策略在晚期及局部进展期人群中的疗效与生存获益，同时也有多个早期研究探索新机制、新靶点的潜力。

• 其中，结直肠癌板块持续推进KRAS G12C、BRAF V600E等分子分型的靶向组合治疗，胃癌研究聚焦于免疫治疗优化与新型HER2靶向药物应用，胰腺癌与胆道肿瘤则集中于术前新辅助与局部晚期治疗模式升级。

• 值得关注的是，来自中国的多项研究亮相Oral，包括安罗替尼 vs 贝伐珠单抗用于mCRC的III期试验、CLDN18.2 CAR-T治疗胃癌的II期研究等，展现了中国力量在全球消化道肿瘤研究中的崭露头角。

整体来看，本届ASCO年会反映出消化系统肿瘤治疗正迈向更精细化、个体化的新时代。为此，【ONCO前沿】特整理消化系统肿瘤最新Oral摘要题目等相关信息，让我们一同揭晓！

中文标题：BREAKWATER研究：encorafenib + 西妥昔单抗 + mFOLFOX6一线治疗BRAF V600E突变转移性结直肠癌的无进展生存期与更新的总生存期分析

英文标题：First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses.

讲者：Elena Elez, MD, PhD | Department of Medical Oncology, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC

中文标题：CheckMate 8HW研究扩展分析：纳武利尤单抗联合伊匹木单抗 vs 化疗或单药纳武利尤单抗用于MSI-H/dMMR转移性结直肠癌的疗效比较

英文标题：Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW.

讲者：Heinz-Josef Lenz, MD | University of Southern California Norris Comprehensive Cancer Center

中文标题：ANCHOR研究：安罗替尼 vs 贝伐珠单抗联合标准一线化疗用于RAS/BRAF野生型、不可切除转移性结直肠癌患者的多中心、前瞻性、随机、III期临床试验

英文标题：Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial).

讲者：丁克峰教授 | 浙江大学医学院附属第二医院

中文标题：III期结肠癌中，ctDNA指导的辅助化疗强化策略：AGITG dynamic-III随机试验（AGITG与CCTG联合研究）ctDNA阳性队列的主要分析结果

英文标题：ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG).

讲者：Jeanne Tie, MD, FRACP, MBChB | Department of Medical Oncology, Peter MacCallum Cancer Centre and Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research

中文标题：Alliance N0147研究：无需组织样本的循环肿瘤DNA检测与FOLFOX辅助化疗患者预后之间的关系

英文标题：Tissue-free circulating tumor DNA assay and patient outcome in a phase III trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147).

讲者：Frank A. Sinicrope, MD | Mayo Clinic Rochester

中文标题：可切除性结直肠腹膜转移患者的围手术期系统治疗：CAIRO6多中心随机III期临床试验

英文标题：Perioperative systemic therapy for resectable colorectal peritoneal metastases: A multicenter randomized phase 3 trial (CAIRO6).

讲者：Ignace De Hingh, MD, PhD | Catharina Cancer Institute

中文标题：CodeBreaK 101（Ib期）研究：KRAS G12C突变转移性结直肠癌中索托拉西布+帕尼单抗+FOLFIRI的长期安全性与疗效

英文标题：Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 (phase 1b).

讲者：John H. Strickler, MD | Duke University Medical Center

中文标题：第二代KRAS G12C抑制剂olomorasib联合西妥昔单抗治疗KRAS G12C突变晚期结直肠癌的疗效与安全性

英文标题：Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in KRAS G12C-mutant advanced colorectal cancer.

讲者：Antoine Hollebecque, MD | Institut Gustave Roussy

中文标题：KANDLELIT-001研究：KRAS G12C抑制剂MK-1084用于KRAS G12C突变晚期结直肠癌的研究结果

英文标题：The KRAS G12C inhibitor MK-1084 for KRAS G12C–mutated advanced colorectal cancer (CRC): Results from KANDLELIT-001.

讲者：Iwona A. Lugowska, MD, PhD | Maria Sklodowska-Curie National Research Institute and Oncology Centre

中文标题：CheckMate 577研究：术前放化疗 + 术后纳武利尤单抗辅助治疗食管癌或胃食管结合部癌的总生存期首次分析

英文标题：Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577.

讲者：Ronan Joseph Kelly, MD, MBA, FASCO | Charles A. Sammons Cancer Center at Baylor University Medical Center

中文标题：LEAP-015研究：仑伐替尼 + 帕博利珠单抗 + 化疗 vs 单纯化疗用于晚期胃食管腺癌的随机III期研究

英文标题：Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced, metastatic gastroesophageal adenocarcinoma: The phase 3, randomized LEAP-015 study.

讲者：Sun Young Rha, MD, PhD | Yonsei Cancer Center, Yonsei University College of Medicine

中文标题：DESTINY-Gastric04研究主要分析：T-DXd vs 雷莫芦单抗+紫杉醇二线治疗HER2阳性不可切除/转移性胃癌或胃食管结合部腺癌的随机III期试验

英文标题：Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study.

讲者：Kohei Shitara, MD | National Cancer Center Hospital East

中文标题：CT041-ST-01研究：靶向Claudin18.2的CAR-T细胞治疗（Satri-cel） vs 医生选择治疗用于既往接受过治疗的晚期胃癌/胃食管结合部癌的随机II期研究主要结果

英文标题：Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01).

讲者：齐长松教授 | 北京大学肿瘤医院

中文标题：术前mFOLFIRINOX vs PAXG方案治疗I-III期胰腺导管腺癌的随机III期研究结果

英文标题：Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma.

讲者：Michele Reni, MD | Department of Medical Oncology, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University

中文标题：PANOVA-3研究：TTFields联合吉西他滨+白蛋白紫杉醇用于局部晚期胰腺导管腺癌的III期研究

英文标题：PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC).

讲者：Vincent J. Picozzi, MD, MMM | Virginia Mason Medical Center